We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




LGC Standards Opens First Chinese Office

By LabMedica International staff writers
Posted on 29 Apr 2009
LGC Standards (Teddington, UK) has opened its first office in Beijing, China, signaling a milestone in the company's international development. More...
The new office will enable the company to bring its range of laboratory quality products and services to the Chinese market.

LGC Standards provides a range of products and services for measurement and laboratory control through the quick and efficient supply of reference materials and proficiency testing schemes. The company will be able to support Chinese laboratories directly by offering logistical and technical advice in their local language.

Dr Matthias Brommer, director, LGC Standards said: "The opening of our first Chinese office clearly demonstrates that LGC Standards is committed to providing global quality management solutions for laboratories worldwide. Our Chinese team will focus on supplying laboratories in the pharmaceutical, environmental, food, industrial, and forensic sectors with reference materials and proficiency testing schemes to support laboratory quality."

In welcoming LGC China to the Group, David Richardson, Chief Executive of LGC, commented, "Our new office provides an excellent opportunity for LGC to serve the Chinese scientific community and gives us a base from which to partner with local businesses on future projects. Our investment strengthens LGC's position as an international leader in reference materials.”

The company supplies over 20,000 reference materials, pharmaceutic impurity reference standards, proficiency testing and training in analytical quality. LGC Standards has offices in France, Germany, Italy, Poland, Spain, Sweden, China, and the UK, a joint venture presence in India, and representatives in Bulgaria, Czech Republic, Finland, Hungary, Ireland, Romania, Turkey, and the United States.

LGC is an international science-based company and market leader in diagnostic, analytical, and forensic services and reference standards. A progressive and innovative enterprise, LGC operates in socially responsible fields underpinning the safety, health, and security of the public and the regulation of industry, for U.K. government departments, and blue chip clients.

Related Links:

LGC Standards




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
Automatic CLIA Analyzer
Shine i6000
Thyroid Test
Anti-Thyroid EIA Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Signatera uses ctDNA analysis to identify residual tumor-derived genetic material after definitive treatment (image credit: Adobe Stock)

Blood-Based MRD Test Predicts Recurrence Risk After Lung Cancer Surgery

Assessing recurrence risk after surgery for early-stage non-small cell lung cancer remains challenging, complicating adjuvant therapy and surveillance decisions. Blood-based molecular residual disease... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Type 1 diabetes affects more than 9 million people worldwide and can begin years before symptoms appear, making early identification of at-risk children difficult (Image Credit: iStock)

Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk

Type 1 diabetes (T1D) affects more than 9 million people worldwide, including 1.8 million children and adolescents, and often begins years before symptoms appear. Early identification of children who are... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.